Lin Li, Chen Dong, Li Shuangyue, Wang Tiantian
Department of Hematology, The Affiliated People's Hospital of Ningbo University, Ningbo, Zhejiang, China.
Heliyon. 2024 Jul 1;10(13):e33935. doi: 10.1016/j.heliyon.2024.e33935. eCollection 2024 Jul 15.
The resistance of multiple myeloma (MM) to bortezomib (BTZ) has brought multiple challenges to its clinical use. Numerous ginsenosides have potential anti-tumor effects, however, the research on the role of Rg1 in MM has not been reported.
To examine the inhibitory impact of Rg1 on the growth of MM and reduce the drug resistance of MM to BTZ through and experiments, and to explore their potential mechanism.
BTZ drug-resistant cell line RPMI8226R was constructed. Mouse tumor-bearing model was developed by abdominal subcutaneous injection of MM cells. MM cells were treated with AMPK inhibitor Compound C or autophagy inhibitor Chloroquine together with Rg1. RPMI8226R cells were treated with BTZ and Rg1. Cell multiplication was detected using Methylthiazolyldiphenyl-tetrazolium bromide assay. Apoptosis was assessed using flow cytometry. Immunofluorescence assay was employed to assess the autophagy markers LC3. Western blot was utilized to assess the protein expression. Immunohistochemistry was used to detect cell proliferation and apoptosis in tumor tissues.
experiments demonstrated that Rg1 could hinder the proliferation of MM cells, promote apoptosis and enhance autophagy. Rg1 could also increase the sensitivity of RPMI8226R to BTZ. In vivo experiments illustrated that Rg1 could hinder the development of MM cells in mice, weaken the proliferation of tumor cells and enhance their apoptosis. Further study found that the anti-MM impact of Rg1 was linked to AMPK-mTOR pathway, the autophagy degree of RPMI8226R was higher than that of RPMI8226, and that Rg1 could inhibit MM and overcome drug resistance through autophagy induced by AMPK-mTOR pathway.
Rg1 has significant anti-MM effect and can overcome BTZ resistance, and its potential mechanism is related to the regulation of autophagy induced by AMPK-mTOR pathway. Rg1 is a promising adjuvant drug for the treatment of MM.
多发性骨髓瘤(MM)对硼替佐米(BTZ)的耐药性给其临床应用带来了多重挑战。众多人参皂苷具有潜在的抗肿瘤作用,然而,关于Rg1在MM中的作用研究尚未见报道。
通过体外和体内实验,研究Rg1对MM生长的抑制作用并降低MM对BTZ的耐药性,探讨其潜在机制。
构建BTZ耐药细胞系RPMI8226R。通过腹腔皮下注射MM细胞建立小鼠荷瘤模型。MM细胞用AMPK抑制剂Compound C或自噬抑制剂氯喹与Rg1共同处理。RPMI8226R细胞用BTZ和Rg1处理。采用甲基噻唑基二苯基四氮唑溴盐法检测细胞增殖。采用流式细胞术评估细胞凋亡。采用免疫荧光法检测自噬标志物LC3。采用蛋白质印迹法评估蛋白质表达。采用免疫组织化学法检测肿瘤组织中的细胞增殖和凋亡。
体外实验表明,Rg1可抑制MM细胞增殖,促进细胞凋亡并增强自噬。Rg1还可增加RPMI8226R对BTZ的敏感性。体内实验表明,Rg1可抑制小鼠体内MM细胞的生长,减弱肿瘤细胞的增殖并增强其凋亡。进一步研究发现,Rg1的抗MM作用与AMPK-mTOR通路有关,RPMI8226R的自噬程度高于RPMI8226,且Rg1可通过AMPK-mTOR通路诱导的自噬抑制MM并克服耐药性。
Rg1具有显著的抗MM作用,可克服BTZ耐药性,其潜在机制与AMPK-mTOR通路诱导的自噬调节有关。Rg1是一种有前景的MM治疗辅助药物。